Related Experiment Video
Updated: Jun 24, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Bacillus Calmette-Guérin for upper tract urothelial cancer: is there a role?
Ardeshir R Rastinehad1, Arthur D Smith
1Department of Urology, North Shore-Long Island Jewish Health System, New Hyde Park, New York 11040, USA. nycurology@gmail.com
Since the first reported case of using adjuvant topical immunotherapy utilizing bacillus Calmette-Guérin (BCG) was published by Herr and associates, several institutions have utilized numerous agents for topical infusion therapies (BCG, Mitomycin, Epirubicin, Thiotepa or combination therapy of BCG/INF) as adjuncts in the treatment of upper tract papillary transitional cell carcinoma. A comprehensive review of the current data in the treatment of upper tract transitional cell carcinoma (Ta/T1 disease) with adjuvant BCG therapy was completed. Currently, the efficacy of adjuvant BCG therapy was not demonstrated.
Since the first reported case of using adjuvant topical immunotherapy utilizing bacillus Calmette-Guérin (BCG) was published by Herr and associates, several institutions have utilized numerous agents for topical infusion therapies (BCG, Mitomycin, Epirubicin, Thiotepa or combination therapy of BCG/INF) as adjuncts in the treatment of upper tract papillary transitional cell carcinoma. A comprehensive review of the current data in the treatment of upper tract transitional cell carcinoma (Ta/T1 disease) with adjuvant BCG therapy was completed. Currently, the efficacy of adjuvant BCG therapy was not demonstrated.
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Urinary Tract Calculi VI: Surgical Management
Urinary Tract Calculi I: Introduction
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Urinary Tract Calculi V: Nursing Management

